Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on X:
“As an oncologist and researcher, I truly value the importance of targeting TP53.
Interim phase 1/2 data of Rezatapopt (PC14586) in TP53 Y220C–mutated tumors:
- ORR 33% overall, 43% in ovarian cancer
- mDOR 6.2 mo. This could be a turning point for resistant cancers.”
More from Elvina Almuradova on OncoDaily.